

References

I-117

1. Chiavenna S, Jaworski J, Vendrell A. State of the art in anti-cancer mAbs. *J Biomed Sci*, 2017;24(1),15.
2. Lau, S C, Chung V, Lim D, et al. Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: A retrospective review. *J Oncol. Pharmacy Practice*. 2014;20(2): 83-87.
3. Lupini L, Bassi C, Negrini M, et al. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. *BMC Cancer*. 2015;15:808.
4. Moretto R, Cremolini C, Rossini D, et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. *The Oncologist*. ISSN: 1549-490X, 2016;21 (8), pp. 988-94.
5. Peeters M, Karthaus M, Rivera F, et al. Panitumumab in metastatic colorectal cancer: The importance of tumor RAS status. *Drugs*. 2015;75(7):731-748.
6. Thomson Micromedex DrugDex Compendium®. Panitumumab. 2017.
7. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Panitumumab. 2017.
8. Vectibix® (panitumumab) for injection [package insert]. Thousand Oaks, CA. Amgen. Revised 06/2017.
9. National Comprehensive Cancer Network (NCCN). Panitumumab. NCCN Drugs & Biologics Compendium®. 2019.
10. Kohne CH, Karthaus M, Mineur L, et al. Impact of primary tumor location and early tumor shrinkage on outcomes in patients with RAS wild-type metastatic colorectal cancer following first-line FOLFIRI plus panitumumab. *Drugs in R&D*. 2019;19(3):267-275.